Check out the on-demand symposium recording from the European Respiratory Society congress 2020 by clicking here. Learn how C-reactive protein (CRP) point-of-care testing can be a valuable diagnostic and clinical decision-making tool in relation to COVID-19, and how it may also inform antibiotic prescribing for acutely exacerbated chronic obstructive pulmonary disease (COPD) patients.
Learn about the value of CRP point-of-care testing for COPD and antimicrobial in the context of COVID-19
The European Respiratory Society congress (ERS) was held on 7–9 September 2020 and delivered the latest innovations in respiratory medicine to over 33,000 delegates.
myPOCacademy hosted a virtual symposium covering CRP point-of-care testing in the time of COVID-19 and for the reduction of antibiotic prescribing in acutely exacerbated COPD patients, watched live by nearly 500 healthcare professionals.
Hear expert perspectives on the value of C-reactive protein (CRP) point-of-care testing (POCT) in the context of COVID-19 by watching the on-demand symposium recording which is now available exclusively on myPOCacademy.
Featuring expert opinion from front-line healthcare staff from around the world, discussions centered around the following topics:
- CRP level as an inflammatory marker for severity and risk assessment in COVID-19
- CRP POCT for identification of patients at high risk of severe outcomes in COVID-19
- CRP POCT for optimal allocation of hospital and intensive care unit resources
- CRP POCT to aid clinical decision-making and guide antibiotic prescribing in patients presenting with symptoms of respiratory tract infections
- The role of CRP POCT in the fight against anti-microbial resistance
- CRP POCT as a diagnostic strategy in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (COPD) in primary care (the PACE study)
Click here to watch the ERS symposium recording in full.
© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.
The American Diabetes Association standards of care - 2023 guidelines provide recommendations for healthcare providers regarding cardiovascular disease (CVD) and risk management in people with diabetes. The authors highlight that atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are leading causes of morbidity and mortality for people with diabetes, noting that simultaneously addressing cardiovascular (CV) risk factors can con...
American Diabetes Association recommendations for cardiovascular disease in diabetesenAccess Now
The Kidney Disease: Improving Global Outcomes (KIDGO) 2022 clinical practice guidelines are based on a systematic review of evidence and aim to assist health care professionals with their decision making for people with diabetes and chronic kidney disease (CKD). The authors highlight that by 2045, 784 million people are estimated to have diabetes globally, of whom ≥40% will develop CKD, potentially leading to kidney failure requiring dialysis or ...
KIDGO clinical practice guidelines: diabetes management in chronic kidney diseaseenAccess Now
The objective of this longitudinal cohort study was to determine the prevalence of chronic kidney disease (CKD) and associated risk factors in a rural South African population. The authors note that infectious and non-communicable disease are a substantial risk for CKD in Africa, but that heterogeneity in assessment and diagnostic criteria hamper the interpretation of prevalence.
Chronic kidney disease prevalence and risks in rural South AfricaenAccess Now